A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective

Journal of Medical Economics

Volumn 13, Issue 1, 2010, Pages 148-161

  Brereton, Nic ^a   Bodger, Keith ^b   Kamm, Michael A ^c,d   Hodgkins, Paul ^e   Yan, Songkai ^e   Akehurst, Ron ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e SHIRE   (United States)

Author keywords

Cost effectiveness; Mesalazine; Ulcerative colitis

Indexed keywords

MESALAZINE; PREDNISONE;

ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG FORMULATION; DRUG TREATMENT FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PROBABILITY; QUALITY OF LIFE; RELAPSE; REMISSION; ULCERATIVE COLITIS; UNITED KINGDOM;

EID: 77149141143     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903562861     Document Type: Article

References (33)

1. Carter MJ, Lobo AJ, Travis SPL; on behalf of the IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(SupplV):vl-16
2. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med 2008;50:1261-1272
3. Actis GC, Pazienza P, Rosina F. Mesalamine for inflammatory bowel disease: recent reappraisals. Inflamm Allergy Drug Targets 2008;7:1-5
4. Mezavant XL 1200mg, gastro-resistant, prolonged release tablets. Summary of Product Characteristics. Available from http://emc.medicines.org.uk
5. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMX. Inflamm Bowel Dis 2005;11:421-427
6. Asacol 400mg MR tablets, Summary of Product Characteristics. Available from http://emc.medicines.org.uk
7. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007;5:95-102
8. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007;132:66-75
9. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis 2009;15:1-8
10. National Institute for Health and Clinical Excellence (June 2008) Section 5.6.1 of Guide to the Methods of Technology Appraisal. Last accessed December 9, 2009: http://www.nice.org.uk/media/B52/A7/TAMethodsGuide-UpdatedJune2008.pdf
11. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of subjects with quiescent ulcerative colitis. Am J Med 2003;114:39-43
12. Lennard-Jones JE, Longmore AJ, Newell AC, et al. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut 1960;1:217
13. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11
14. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006;23:577-585
15. Kane SV, Hanauer SB. National adherence rates with IBD therapy: PO vs PR. Am J Gastroenterol 2001;96:S296
16. Kane SV, Sumner M, Solomon D, et al. Twelve-month persistence with 5-aminosalicylic acid therapy: results from a large pharmacy database. Poster presented at the 40th Annual Digestive Disease Week, Chicago, IL, USA; May 30-June 4, 2009
17. Shaya FT, El Khoury AC, Wong W, et al. Persistence with pharmacotherapy for gastrointestinal disease: Associated costs of health care. P&T 2006;31:657-665
18. Katsanos KH, Vermeire S, Christodoulou DK, et al. Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion 2007;75:113-121
19. Van Staa TP, Card T, Logan RF, et al. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005;54:1573-1578
20. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100:1345-1353
21. Carter MJ, Lobo AJ, Travis SPL; on behalf of the IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(SupplV):v1-16
22. Travis SPL, Stange EF, Lémann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2008;2:24-62
23. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-535
24. Bowel Cancer Services: Costs and Benefits: York Health Economics Consortium & Scharr.:, 2008
25. British National Formulary (BNF). Available at www.bnf.org.uk. Accessed July, 2008
26. Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004;53:1471-1478
27. Bassi A, Bodger K. Health state utilities & willingness-to-pay in inflammatory bowel disease (IBD) - a study of feasibility & validity. Aliment Pharmacol Ther 2005;21:197-198 (Abstract)
28. Luces C, Brown E, Bodger K. Satisfaction with healthcare in inflammatory bowel disease: influence of patient characteristics. Gut 2007;56(Suppl 2):A145 (Abstract)
29. Ness RM, Holmes AM, Klein R, et al. utility valuations for outcome states of colorectal cancer. Am J Gastroenterol 1999;94:1650-1657
30. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-1629
31. Sninsky CA, Cort DH, Shanchan E, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicentre study. Ann Intern Med 1991;115:350-355
32. Yen E, Kane S, Ladabaum U. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis. Am J Gastroenterol 2008;103:1-12
33. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99:1371-1385